GLP-1 may slow biological aging

Automated excerpt

Semaglutide, a widely used weight loss drug sometimes sold as Ozempic or Wegovy, slowed biological aging across multiple epigenetic clocks in a randomized, double-blind, placebo-controlled clinical trial. However, the study found compared to the placebo group:Participants treated with semaglutide exhibited a broad pattern of slower biological aging across epigenetic clocks linked to inflammation and blood, brain, heart, kidney, liver and metabolic health. The drug slowed the pace of biological aging by 9 %, as measured by the DunedinPACE epigenetic clock.

Selected automatically from source text; not independently written or fact-checked. Read the original for full context.